BACKGROUND: Few studies have examined risk for severe symptoms during early cancer survivorship. By using baseline data from the American Cancer Society's Study of Cancer Survivors-I, the authors examined cancer survivors with high symptom burden, identified risk factors associated with high symptom burden, and evaluated the impact of high symptom burden on health-related quality of life (HRQoL) 1 year postdiagnosis. METHODS: Participants were enrolled from 11 state cancer registries approximately 1 year after diagnosis and were surveyed by telephone or mail. The outcomes measures used were the Modified Rotterdam Symptom Checklist and the Profile of Mood States-37 (to assess symptom burden) and the Satisfaction with Life Domains Scale-Cancer (to assess HRQoL). RESULTS: Of 4903 survivors, 4512 (92%) reported symptoms related to their cancer and/or its treatment. Two-step clustering yielded 2 subgroups, 1 with low symptom burden (n = 3113) and 1 with high symptom burden (n = 1399). Variables that were associated with high symptom burden included lung cancer (odds ratio [OR], 2.27), metastatic cancer (OR, 2.05), the number of comorbid conditions (OR, 1.76), remaining on active chemotherapy (OR, 1.93), younger age (OR, 2.31), lacking insurance/being underinsured (OR, 1.57), having lower income (OR, 1.61), being unemployed (OR, 1.27), and being less educated (OR, 1.29). Depression, fatigue, and pain had the greatest impact on HRQoL in survivors with high symptom burden, who also had lower HRQoL (P < .0001). CONCLUSIONS: More than 1 in 4 cancer survivors had high symptom burden 1 year postdiagnosis, even after treatment termination. These results indicate a need for continued symptom monitoring and management in early post-treatment survivorship, especially for the underserved.
BACKGROUND: Few studies have examined risk for severe symptoms during early cancer survivorship. By using baseline data from the American Cancer Society's Study of Cancer Survivors-I, the authors examined cancer survivors with high symptom burden, identified risk factors associated with high symptom burden, and evaluated the impact of high symptom burden on health-related quality of life (HRQoL) 1 year postdiagnosis. METHODS:Participants were enrolled from 11 state cancer registries approximately 1 year after diagnosis and were surveyed by telephone or mail. The outcomes measures used were the Modified Rotterdam Symptom Checklist and the Profile of Mood States-37 (to assess symptom burden) and the Satisfaction with Life Domains Scale-Cancer (to assess HRQoL). RESULTS: Of 4903 survivors, 4512 (92%) reported symptoms related to their cancer and/or its treatment. Two-step clustering yielded 2 subgroups, 1 with low symptom burden (n = 3113) and 1 with high symptom burden (n = 1399). Variables that were associated with high symptom burden included lung cancer (odds ratio [OR], 2.27), metastatic cancer (OR, 2.05), the number of comorbid conditions (OR, 1.76), remaining on active chemotherapy (OR, 1.93), younger age (OR, 2.31), lacking insurance/being underinsured (OR, 1.57), having lower income (OR, 1.61), being unemployed (OR, 1.27), and being less educated (OR, 1.29). Depression, fatigue, and pain had the greatest impact on HRQoL in survivors with high symptom burden, who also had lower HRQoL (P < .0001). CONCLUSIONS: More than 1 in 4 cancer survivors had high symptom burden 1 year postdiagnosis, even after treatment termination. These results indicate a need for continued symptom monitoring and management in early post-treatment survivorship, especially for the underserved.
Authors: Tenbroeck Smith; Kevin D Stein; C Christina Mehta; Chiewkwei Kaw; James L Kepner; Trent Buskirk; Jeremy Stafford; Frank Baker Journal: Cancer Date: 2007-01-01 Impact factor: 6.860
Authors: Christine Miaskowski; Bruce A Cooper; Steven M Paul; Marylin Dodd; Kathryn Lee; Bradley E Aouizerat; Claudia West; Maria Cho; Alice Bank Journal: Oncol Nurs Forum Date: 2006-09-01 Impact factor: 2.172
Authors: Barbara Given; Charles W Given; Alla Sikorskii; Sangchoon Jeon; Ruth McCorkle; Victoria Champion; David Decker Journal: J Pain Symptom Manage Date: 2007-12-26 Impact factor: 3.612
Authors: Eric Winer; Julie Gralow; Lisa Diller; Beth Karlan; Patrick Loehrer; Lori Pierce; George Demetri; Patricia Ganz; Barnett Kramer; Mark Kris; Maurie Markman; Robert Mayer; David Pfister; Derek Raghavan; Scott Ramsey; Gregory Reaman; Howard Sandler; Raymond Sawaya; Lynn Schuchter; John Sweetenham; Linda Vahdat; Richard L Schilsky Journal: J Clin Oncol Date: 2008-12-22 Impact factor: 44.544
Authors: Amye J Tevaarwerk; Ju-Whei Lee; Abigail Terhaar; Mary E Sesto; Mary Lou Smith; Charles S Cleeland; Michael J Fisch Journal: Cancer Date: 2015-12-21 Impact factor: 6.860
Authors: Sarah A Kelleher; Caroline S Dorfman; Jen C Plumb Vilardaga; Catherine Majestic; Joseph Winger; Vicky Gandhi; Christine Nunez; Alyssa Van Denburg; Rebecca A Shelby; Shelby D Reed; Susan Murphy; Marie Davidian; Eric B Laber; Gretchen G Kimmick; Kelly W Westbrook; Amy P Abernethy; Tamara J Somers Journal: Contemp Clin Trials Date: 2017-04-11 Impact factor: 2.226
Authors: Martijn J L Bours; Bernadette W A van der Linden; Renate M Winkels; Fränzel J van Duijnhoven; Floortje Mols; Eline H van Roekel; Ellen Kampman; Sandra Beijer; Matty P Weijenberg Journal: Oncologist Date: 2016-02-24
Authors: Maya F Ilowite; Hasan Al-Sayegh; Clement Ma; Veronica Dussel; Abby R Rosenberg; Chris Feudtner; Tammy I Kang; Joanne Wolfe; Kira Bona Journal: Cancer Date: 2018-09-14 Impact factor: 6.860
Authors: William A Wood; Allison M Deal; Amy Abernethy; Ethan Basch; Claudio Battaglini; Yoon Hie Kim; Julia Whitley; Charlotte Shatten; Jon Serody; Thomas Shea; Bryce B Reeve Journal: Biol Blood Marrow Transplant Date: 2012-12-16 Impact factor: 5.742